Comparison of the action of NSC 680410 and STI571 in chronic myelogenous leukemia cells in vitro.

被引：0
|
作者：
Mow, BM
Hallgren, CG
Svingen, PA
Tefferi, A
Sausville, EA
Kaufmann, SH
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Div Oncol Res, Rochester, MN USA
[3] NCI, Dev Therapeut Program, Bethesda, MD 20892 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1493
引用
收藏
页码：346A / 346A
页数：1
相关论文
共 50 条
  • [1] Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
    Mow, BMF
    Chandra, J
    Svingen, PA
    Hallgren, CG
    Weisberg, E
    Kottke, TJ
    Narayanan, VL
    Litzow, MR
    Griffin, JD
    Sausville, EA
    Tefferi, A
    Kaufmann, SH
    BLOOD, 2002, 99 (02) : 664 - 671
  • [2] Effects of STI571 on acute myelogenous leukemia (AML) cells in vitro.
    Scappini, B
    Onida, F
    Kantarjian, H
    Li, D
    Keating, MJ
    Beran, M
    BLOOD, 2000, 96 (11) : 114A - 115A
  • [3] Effects of the bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on leukemic cells in vitro.
    Chandra, J
    Mow, B
    Weisberg, E
    Griffin, J
    Sausville, EA
    Tefferi, A
    Kaufmann, SH
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3768S - 3769S
  • [4] Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells
    Kawauchi, K
    Ogasawara, T
    Yasuyama, M
    Ohkawa, S
    BLOOD CELLS MOLECULES AND DISEASES, 2003, 31 (01) : 11 - 17
  • [5] The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia
    Sato, N
    Narita, M
    Takahashi, M
    Yagisawa, K
    Liu, A
    Abe, T
    Nikkuni, K
    Furukawa, T
    Toba, K
    Aizawa, Y
    HEMATOLOGICAL ONCOLOGY, 2003, 21 (02) : 67 - 75
  • [6] STI571 can restore expression of CD62L in chronic myelogenous leukemia cells.
    Fruehauf, S
    Topaly, J
    Paschka, P
    Capdeville, R
    Gschaidmeier, H
    Hochhaus, A
    Ho, AD
    BLOOD, 2000, 96 (11) : 343A - 343A
  • [7] Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells
    Huguet, Florence
    Giocanti, Nicole
    Hennequin, Christophe
    Croisy, Martine
    Touboul, Emmanuel
    Favaudon, Vincent
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (02) : 398 - 406
  • [8] Effect of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro
    Svingen, PA
    Tefferi, A
    Kottke, TJ
    Kaur, G
    Narayanan, VL
    Sausville, EA
    Kaufmann, SH
    CLINICAL CANCER RESEARCH, 2000, 6 (01) : 237 - 249
  • [9] BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
    Donato, NJ
    Wu, JY
    Stapley, J
    Gallick, G
    Lin, H
    Arlinghaus, R
    Talpaz, M
    BLOOD, 2003, 101 (02) : 690 - 698
  • [10] Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia
    K. Miyachi
    A. Ihara
    R. W. Hankins
    R. Murai
    S. Maehiro
    H. Miyashita
    Clinical Rheumatology, 2003, 22 : 329 - 332
12345